Methadone in maintenance treatment of narcotic addicts; joint revision of conditions for use; interim maintenance treatment; human immunodeficiency virus disease counseling--FDA and SAMHSA. Final rule.
The Food and Drug Administration (FDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) formerly the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) are revising the conditions for the use of methadone in the maintenance treatment of narcotic addicts. The final rule allows, contingent on FDA and State approval, public and nonprofit private narcotic treatment programs to provide interim maintenance treatment to patients awaiting placement in comprehensive maintenance treatment and to require all narcotic treatment programs to provide counseling on preventing exposure to, and the transmission of, human immunodeficiency virus (HIV) disease.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control / Q000635:transmission; D003140:Communicable Disease Control / Q000331:legislation & jurisprudence; D003376:Counseling / Q000331:legislation & jurisprudence; D006801:Humans; D008691:Methadone / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D016320:Substance Abuse Treatment Centers / Q000331:legislation & jurisprudence*; D014481:United States; D014483:United States Dept. of Health and Human Services; D014486:United States Food and Drug Administration